Reason for request
Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives. |
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
a6b2tj0zdBuRXsK9
